Surveillance testing is performed after primary treatment for colorectal cancer (CRC), but it is unclear if the intensity of testing decreases time to detection of recurrence or affects patient survival.
C olorectal cancer (CRC) is the third most common cancer and second leading cause of cancer death for men and women in the United States, estimated to affect 140 250 patients in 2018. 1 Approximately 80% of patients with CRC present with localized disease (American Joint Committee on Cancer [AJCC], stage I, II, or III) for which surgical therapy is curative, and as of 2014, patients with CRC represented the third largest group of cancer survivors. 2 After completion of definitive treatment, surveillance is recommended with the goal of improving disease-specific and overall survival by detecting disease recurrence or a second primary cancer early, such that a patient has an opportunity for potentially curative surgery. Additionally, surveillance can be effective in monitoring long-term treatment toxicity, managing patient anxiety, and ensuring continuation of cancer survivorship care.
However, the optimal surveillance strategy is unknown, and recent data from randomized trials have not demonstrated significant survival benefit from intensive follow-up. 3, 4 Data to inform which testing is most beneficial and how often testing should be performed is limited, and the survival benefit of surveillance in contemporary practice is unknown. National and international consensus guidelines vary, although many still recommend frequent testing, yet adherence to these guidelines is inconsistent, resulting in both overtesting and undertesting in clinical practice. [5] [6] [7] [8] [9] [10] [11] While the frequency with which intensive testing can identify recurrence early and lead to an intervention that improves outcomes is unknown, recent evidence suggests it would have little clinical effect. The purpose of this study was to determine the association between surveillance intensity and the detection of CRC recurrence and survival within a large US population outside a clinical trial. The hypothesis was that more intensive surveillance would not be associated with earlier detection of recurrence or better overall survival.
Methods

Study Design and Data Sources
Patients 18 years or older who had been diagnosed with stage I, II or III CRC, as defined by the AJCC, and treated with definitive surgical resection in 2006-2007 were identified from the National Cancer Data Base ( Figure 1 ). Demographic data were obtained from predefined National Cancer Database variables, 12 and stage was defined by the seventh edition of the AJCC Cancer Staging Manual. 13 A random sample of up to 10 patients with CRC from each Commission on Cancer facility were selected for detailed primary data collection regarding surveillance testing, recurrence, and treatment as part of the commission's Special Study. Predefined primary data were collected by cancer registrars from a primary chart review of records at the treating facility and physician offices. That data were then merged with corresponding National Cancer Database records. If patients sought care at separate facilities, registrars obtained records from other facilities and outpatient offices. Patient race was included in this study in order to investigate the association between race and surveillance testing intensity. The determination of patient race in this study was derived from predefined National Cancer Database data based on assignment by a Commission on Cancer registrar according to fixed categories.
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The enrollment period (2006) (2007) was chosen to ensure a minimum of 5 years of follow-up for recurrence and diseasespecific survival. Overall survival was assessed over a total of 7 years. Surveillance and recurrence data were collected through December 2012 with vital status through December 2014.
These data were collected via a secure web form housed at the National Cancer Database and provided to the principal investigator as deidentified data in compliance with Health Insurance Portability and Accountability Act (HIPAA). Study analysis was considered exempt by The MD Anderson Cancer Center Institutional Review Board.
The surveillance start date was defined as 90 days after curative resection. Exclusion criteria included the lack of a surveillance start date (due to recurrence, death, or loss to follow-up within 90 days of surgery), lack of tumor site or stage, and nonsurgical management. Registrars screened patients based on the above criteria. If excluded, a new randomly selected patient was assigned prior to data collection.
Ascertainment of Surveillance Testing
To assess surveillance intensity, the observed number of imaging studies-computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography, and carcinoembryonic antigen (CEA) tests-obtained for each patient during the surveillance period was recorded.
Complementary imaging studies performed within 30 days, such as a CT scan of the chest plus a CT scan of the abdomen and pelvis or a CT scan of the chest plus an MRI of the abdomen and pelvis were counted as a single study.
Exposure and Definition of Surveillance Intensity
An observed to expected ratio (O:E ratio) of testing (separately for imaging and CEA) at both the individual and facility level was used to account for differences in risk-related surveillance. The observed number of tests within 3 years was calculated for each patient. The expected number was then estimated based on fixed effects and posterior means of random effects derived from a 2-level random intercept negative binomial model in predicting the observed number, accounting for not only the random effects from hospitals but also the fixed effects including the variables indicated in Table 1 .
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Comparison of the multilevel model to a nonmultilevel model (likelihood-ratio test) indicated a significant clustering effect of testing intensity by facility (P < .001). Therefore, the O:E ratio for each facility was calculated based on the sum of the individuals from that facility. The facility was categorized into highintensity (O:E ratio ≥1) or low-intensity (O:E <1) categories for comparison. Because patients with documented recurrence undergo more testing during evaluation of recurrence, only those who were alive and disease free for at least 3 years were included for the O:E ratio estimation (n = 6279).
To minimize the influence of physician-level bias and the potential to misclassify confirmatory tests in the setting of suspected recurrence as surveillance tests, patients were assigned a surveillance intensity group (high vs low intensity) based on the facility at which they received care. After highand low-intensity facility-based groups were empirically defined, patients who died or developed documented recurrence were reintroduced into the analysis and assigned to the intensity group based on their treatment facility. Analyses were then performed at the individual patient level using a facilitybased high-vs low-intensity assignment.
Primary and Secondary Outcomes
The primary outcome of interest was time to detection of recurrence (locoregional or distant) and cumulative recurrence detection rates, confirmed pathologically or clinically. Prespecified secondary outcomes included resection for recurrent distant disease and overall survival.
Post hoc sensitivity analyses for internal validity were performed for (1) inclusion of only patients with stage II or III cancer in the determination of the O:E ratio estimation; (2) facilities with the highest and lowest quartiles of imaging and CEA testing; (3) hospital-level agreement for intensity by imaging vs CEA; and (4) analysis using missing or unavailable data as a separate category.
Statistical Analysis
Baseline characteristics were compared across intensity groups using the χ 2 test for categorical variables, t test for means, and
Kruskal-Wallis test for medians of continuous variables. Differences in median time to recurrence and confidence intervals were calculated as described by Bonnet-Price. 16 Cumulative recurrence rates, resection rates, and overall survival were determined using the Kaplan-Meier method and compared by logrank tests. Adjusted analyses were performed using multivariable Cox regression, controlling for fixed-effect variables used for intensity estimation. The proportional-hazards assumptions for high vs low intensity was verified graphically using the "loglog" plot, for which the −1n [−1n (survival)] curves of the covariate vs 1n (analysis time) demonstrated reasonable parallel curves. Patients were censored at the time of death, loss to followup, or end of surveillance study period (5 years). Agreement of imaging and CEA intensity was measured in a continuous form using a Bland-Altman plot. The limits of agreement were defined as the mean difference plus or minus a 1.96 standard deviation of the differences.
Two variables, perineural invasion and lymphovascular invasion, had more than 5% missing values. Multiple imputation by chained equations was used to substitute predicted values for missing values with 20 imputed values. Multivariable Cox regression was then performed with results pooled to yield statistical inferences. All tests were 2-sided, with an α of .05; because there was no adjustment for multiple comparisons, statistically significant findings for secondary end points should be interpreted as exploratory. All analyses were performed using SAS software (version 9.1.3; SAS Institute Inc) for data processing and Stata MP (version 13.1; StataCorp) for statistical analyses.
Results
Study Population
Of the 11 100 patients randomly selected for detailed primary data collection (Figure 1 ), 8542 had surveillance testing within 3 years after primary resection and were followed up for a median of 5 years (interquartile range [IQR], 3.75-5 years) as surveillance data collection was truncated at 5 years. Of 8542 patients who underwent surveillance testing, 6279 patients remained disease free at 3 years and were eligible for an O:E ratio estimation. The final study cohort included 8529 patients who had undergone surveillance testing and were treated at a facility allowing for an O:E ratio assignment (Figure 1 ). Demographic data by surveillance intensity are presented in Table 1 , and the cancer characteristics are presented in Table 2 . The overall survival of the cohort for 5 years was 73.7% and 65.6% for 7 years.
Surveillance Intensity
Based on the estimated O:E ratio, 613 facilities were designated low intensity and 562, high intensity for imaging, and 636 facilities were designated low intensity and 539, high intensity based CEA testing frequency. The mean number of imaging tests Table 1 ). The mean number of tests performed was associated with cancer stage (eTable 1 in the Supplement), but stage was not significantly associated with intensity assignment (Table 1) .
Recurrence Detection
There was no significant association between imaging and CEA surveillance intensity and detection of recurrence by multivariable Cox regression adjusting for patient and tumorrelated factors (hazard ratio [HR], 0.99; 95% CI, 0.90-1.09 for imaging and 1.00; 95% CI, 0.91-1.11 for CEA; Table 3 ). Overall 5-year rates of recurrence detection did not significantly differ based on intensity of surveillance imaging (difference, −0.29%; 95% CI, −2.09% to 1.51%) or CEA testing (difference, 0.06%; 95% CI, −1.75% to 1.86%, Table 3 ). The median time to any recurrence detection was 15.1 months (interquartile range [IQR], 8.2-26.3 months) for highintensity imaging vs 16.0 months (IQR, 7.9-27.2 months) for low-intensity imaging (median difference, −0.95; 95% CI, −2.59 to 0.68; Table 3 ). The median time to any recurrence detection was 15.9 months (IQR, 8.5-27.5 months) for the highintensity CEA vs 15.3 months (IQR, 7.9-25.7 months) for lowintensity CEA (median difference, 0.59; 95% CI, −1.33 to 2.51; Table 3 ). The median time to locoregional recurrence detection by imaging was 12.2 months for high-intensity imaging (IQR, 7.6-23.1 months) vs 13.7 months for low-intensity imaging (IQR, 7.2-25.6 months) (median difference, −1.47; 95% CI, −5.12 to 2.17) and was 11.3 months (IQR, 6.6-23.1 months) for high intensity CEA vs 14.1 months (IQR, 8.2-26.2 months) for lowintensity CEA (median difference, −2.76; 95% CI, −5.8 to 0.28). The median time to detection of distant recurrence was 16.0 months (IQR, 8.7-27.6 months) for high-intensity imaging vs 16.6 months (IQR 7.9-27.0 months) for low-intensity imaging (median difference, −0.61; 95% CI, −2.61 to 1.40) and was 17.0 months (IQR, 8.8-29.2 months) for high-intensity CEA vs 15.5 months (IQR, 7.8-26.1) for low-intensity CEA (median difference, 1.45; 95% CI, −0.63 to 3.52).
After stratification by primary tumor site, there was no significant difference in rates of recurrence detection by imaging or CEA surveillance intensity ( Figure 2A and B and eTable 2 in the Supplement). In addition, 5-year rates of recurrence detection were also stratified by stage of the primary tumor, and no significant difference was observed based on intensity of imaging or CEA surveillance (eTable 2).
Resection Rates and Overall Survival
There was no significant difference in the proportion of patients who underwent resection for recurrence at 3 or 5 years by imaging surveillance intensity, for a difference of 0.67% (95% CI, −0.21% to 1.55%) at 3 years and a difference of 0.85% (95% CI, −0.18% to 1.87%) at 5 years nor by CEA intensity for a difference of 0.38% (95% CI, −0.50% to 1.26%) at 3 years and a difference of 0.51% (95% CI, −0.51% to 1.54%) at 5 years (Table 2) . When stratified by stage, there was no significant difference in 5-year resection rates among patients with stage II or III CRC who underwent highintensity vs low-intensity imaging for a difference of 0.89% (95% CI, −0.69% to 2.47%) at 3 years and a difference of 1.33% (95% CI, −0.80% to 3.47%) at 5 years ( Figure 3A and eTable 2 in the Supplement). Similarly, high-intensity CEA testing was not associated with significantly higher resection rates between stage II or III patients for a difference of 0.48% (95% CI, −1.10% to 2.06%) at 3 years and a difference of 1.22% (95% CI, −0.91% to 3.36%) at 5 years ( Figure 3B and eTable 2). Multivariable Cox regression showed no significant difference by imaging (HR, 1.22; 95% CI, 0.99-1.51) or CEA intensity (HR, 1.12; 95% CI, 0.91-1.39) ( Table 3 ).
In addition, 5-and 7-year overall survival rates did not differ significantly based on imaging or CEA intensity. The overall 5-year survival rates in both imaging intensity groups were 73.7% (difference, −0.06%; 95% CI, −1.95% to 1.82%); the 7-year rates were 65.6% in the high-intensity group and 65.5% in the low-intensity group (difference, 0.04%; 95% CI, −2.03% to 2.12%; Table 3 ). Similarly, the overall 5-year survival rates were 74.3% in the highintensity CEA group and 73.1% in the low-intensity group (difference, 1.20%; 95% CI, −0.69% to 3.08%); the 7-year overall survival rates were 66.4% in the high-intensity CEA group and 64.7% in the low-intensity group (difference, 1.71%; 95% CI, −0.37% to 3.78%; Table 3 ). Furthermore, survival rates did not differ significantly based on imaging or CEA intensity when stratifying by tumor site ( Figure 4A -B and eTable 2 in the Supplement). b Differences in median time to detected recurrence and CIs were calculated as described by Bonnet-Price 16 and compared using Kruskal-Wallis test.
c P values were determined using log-rank test for Kaplan-Meier estimates.
d Multivariable Cox regression was used analysis for HRs, which are adjusted for patient and clinical characteristics: patient age, sex, race, comorbidity, socioeconomic status (insurance, income, and education status, population density), tumor site, tumor sequence number, stage, size, histology, grade, lymph nodes assessed, year of diagnosis, lymphovascular invasion, perineural invasion, surgical margin, chemotherapy and radiation therapy, facility type, location, and distance traveled for care (miles).
Multivariable
Cox regression failed to demonstrate a significant association between imaging (HR, 1.01; 95% CI, 0.94-1.08) and CEA surveillance intensity (HR, 0.96; 95% CI, 0.89-1.03) and overall survival (Table 3) .
Post hoc Analyses
Several sensitivity analyses were performed: (1) 
Discussion
In this study of a national population of patients with stage I, II, or III CRC, intensity of follow-up testing by imaging or CEA was not associated with time to detection of disease recurrence. Additionally, no significant association was identified between surveillance testing intensity and overall survival.
These findings differ from historic data regarding the association between follow-up testing and survival after curative treatment of localized CRC. In this study, intensity was empirically defined. Test utilization at high-intensity facilities was consistent with current US guidelines for annual CT (2.9 imaging tests within 3 years) but less frequent than guidelines of every 3 to 6 months for CEA tests (4.3 CEA tests within 3 years). 5, 8, 9, 18 Low-intensity facilities performed follow-up Research Original Investigation Posttreatment Colorectal Cancer Surveillance Testing Intensity and Disease Recurrence testing at rates consistent with less intensive follow-up schedules, including at least 1 imaging test and 1 CEA test during the first 3 years of follow-up. 6, 7, 19 Current surveillance recommendations for more intensive follow-up are derived from historical data associating intensive surveillance with an earlier time to detection of recurrence and therefore improved overall but not cancer-specific survival. [20] [21] [22] [23] However, 2 randomized 3, 4 trials of high-intensity surveillance vs minimal follow-up failed to demonstrate improved survival, and thus have called these traditional assumptions into question, leaving recent guidelines unable to recommend an optimal strategy.
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The Follow-up After Colorectal Surgery (FACS) 3 randomized trial showed a small increase in rates of curative resection with intensive imaging and CEA testing compared with minimal follow-up. However, the absolute difference was only 5%, and combining CEA and imaging did not increase resection rates. Moreover, there was no significant difference in the number of deaths with intensive follow-up. Similarly, the CEAwatch trial, 25 found a higher proportion of recurrences amenable to curative resection among patients followed up in an intensive surveillance protocol compared with standard followup, although overall recurrence rates in this study were low (7.5%) and overall survival was not assessed. The Gruppo Italiano Lavoro per la Diagnosi Anticipata (GILDA) 4 trial compared intensive testing with semiannual liver ultrasound, annual colonoscopy, and chest imaging with less intensive follow-up with 2 ultrasounds within 16 months and colonoscopy at years 1 and 4 for patients with Duke stage B2 and C CRC. Although recurrence was detected at a mean 5.9 months earlier with intensive surveillance, there was no significant difference in overall survival. Earlier evidence in support of high-intensity testing are likely attributable to early recurrence from occult metastases present at diagnosis, effects mitigated by the marked improvements in preoperative staging over time. 3 It is also plausible that the historical benefits from follow-up may stem, at least in part, from regular contact with a clinician, as opposed to earlier detection of recurrent disease. Additional insight from the Assessment of Frequency of Surveillance after Curative Resection in Patients with Stage II and III Colorectal Cancer (COLOFOL) 26 trial, comparing the effect of high vs low intensity surveillance on 5-year disease-specific survival and overall survival is highly anticipated.
In the present study, as in recent trials, absolute rates of salvage resection were up to 1.3% higher in facilities with highintensity imaging surveillance among patients with stage III cancer; however, this small difference is not likely to be clinically meaningful. Moreover, rates of recurrence detection did not differ between high and low intensity, suggesting that recurrences are identified through a combination of imaging, CEA, and symptom-driven evaluation. It is possible that even higher surveillance intensity or higher rates of curative resection for recurrent disease in the high-intensity group could have resulted in a greater effect. This may explain the lack of association of high-intensity CEA testing on rates of salvage surgery, which were lower than those observed with highintensity CEA testing in the FACS 3 or CEAwatch trials. 25 Sensitivity analyses comparing recurrence and survival among patients treated at the highest-vs lowest-quartile facilities showed no overall differences in survival by surveillance intensity. While there was a small observed association with recurrence detection when comparing the highest vs lowest quartile for imaging intensity, this was not associated with significant differences in survival. One explanation for the lack of overall survival effect by surveillance intensity is the low event rate of salvage surgery observed in the present study and in recently reported trials. This study may be underpowered to detect a difference in overall survival based on resection rates, although the absolute difference in overall survival would be expected to be small. Furthermore, low intensity was not equivalent to no follow-up, but rather less follow-up during the first 3 years, when the majority of recurrences occur. It is also possible that patients at highest risk of recurrence (eg, stage IIIC) might receive more intensive surveillance but may also have recurrences not amenable to curative resection. While it is generally accepted that salvage surgery can improve survival, the risk of disease relapse remains high, and the benefit may be limited for some patients. Thus, the value of earlier detection without survival effect is likely to be dependent on the personal values and preferences of the patient, highlighting the importance of individualizing surveillance plans. Surveillance testing is not without potential harm, including false-positive results leading to unnecessary tests or procedures, radiation exposure, contrast toxicity, and other testing-related complications.
Based on these data and the recent FACS trial, current National Comprehensive Cancer Network guideline recommendations (CT testing every 6 months for 3 years) could be considered overtesting given the absence of improvement in recurrence detection or survival. Moreover, these data suggest that the recommendation of 2 CT scans in the first 3 years and CEA testing every 6 months in the first 3 years by the National Institute for Health and Care Excellence in the United Kingdom are appropriate. 19 
Limitations
This study has several limitations. First, this was a retrospective cohort study, and patients were not randomized, nor could individual decision making driving testing frequency be accounted for. Surveillance intensity was assigned based on treatment facility while adjusting for patient factors, but clustering by practice facility helped to control for practice facilitylevel variation. Nevertheless, there could have been additional within-facility variation. Second, because data were collected on up to 10 patients for each facility regardless of volume, it is possible that low-volume facilities could be overrepresented. Third, the cohort was assembled in 2006-2007 and therefore may not reflect contemporary practice. However, patients were selected from 2006 to 2007 to allow at least 5 years of follow-up data regarding surveillance and recurrence and were followed up through 2014 for vital status. Although there have been advances in systemic therapy for metastatic disease over the study period, without significant differences in the detection and treatment of recurrence, these advances similarly affect both the low-intensity and highintensity cohorts, and therefore do not affect the primary findings of this study. Fourth, retrospectively collected data are dependent on the quality of data abstraction. It is possible that if patients completed follow-up or sought treatment at another institution, data loss could occur. Registrars were asked to follow-up with outside institutions in an effort to try to ensure data completeness, but actual data completeness was not measured. Fifth, the empirical definition of high-intensity surveillance in this study included less intensive follow-up than is practiced in some centers, for example, and a benefit of even higher intensity could not be excluded. However, the observed surveillance testing is reflective of contemporary community practice, and therefore provides relevant data for comparison.
Conclusions
Among patients treated for stage I, II, or III CRC, there was no significant association between surveillance intensity and detection of recurrence. The differences in observed/expected (O/E) ratio were plotted against its corresponding means. The limits of agreement were defined as the mean difference (red solid line) ± 1.96 standard deviation of the differences (red dashed line). The plot indicates that the two intensity measurements were considered to be in agreement, with a mean difference of 0.102 (95% limits of agreement -0.861, 1.065) and 5.87% (69/1175) of the facility outside the limits of agreement. There exist 5 facilities with both mean and difference equal to 0 (x=0, y=0).
